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Abstract
Background: Identifying novel TB diagnostics is a major public health priority. We explored the
diagnostic characteristics of antimycobacterial lymphocyte proliferation assays (LPA) in HIV-
infected subjects with latent or active TB.
Methods: HIV-infected subjects with bacille Calmette Guérin (BCG) scars and CD4 counts ≥ 200
cells/mm3 entering a TB booster vaccine trial in Tanzania had baseline in vivo and in vitro immune
tests performed: tuberculin skin tests (TST), LPA and five day assays of interferon gamma (IFN-γ)
release. Assay antigens were early secreted antigenic target 6 (ESAT-6), antigen 85 (Ag85), and
Mycobacterium  tuberculosis  whole cell lysate (WCL). Subjects were screened for active TB at
enrollment by history, exam, sputum smear and culture. We compared antimycobacterial immune
responses between subjects with and without latent or active TB at enrollment.
Results: Among 1885 subjects screened, 635 had latent TB and 13 had active TB. Subjects with
latent TB were more likely than subjects without TB to have LPA responses to ESAT-6 (13.2% vs.
5.5%, P < 0.0001), Ag85 (18.7% vs. 3.1%, P < 0.0001), and WCL (45.7% vs. 17.1%, P < 0.0001).
Subjects with active TB also were more likely than those without active TB to have detectable LPA
responses to ESAT-6 (38.5% vs. 8.1%, P = 0.0001), Ag85 (46.2% vs. 8.5%, P < 0.0001), and WCL
(61.5% vs. 27.0%, P = 0.0053). In subjects with a positive TST, LPA responses to ESAT-6, Ag85 and
WCL were more common during active TB (p < 0.0001 for all tests). In diagnosing active TB, in
vivo and in vitro tests of mycobacterial immune responses had sensitivity and specificity as follows:
TST 84.6% and 65.5%, ESAT-6 LPA 38.5% and 92.0%, Ag85 LPA 46.2% and 91.5%, and WCL LPA
61.5% and 73.0%. Detectable LPA responses were more common in patients with higher CD4
counts, and higher HIV viral loads.
Conclusion:  Lymphoproliferative responses to mycobacteria are detectable during HIV-
associated active TB, and are less sensitive but more specific than TST.
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Background
Tuberculosis (TB) is a major cause of death in HIV-
infected people worldwide [1], yet, current approaches to
TB diagnosis in HIV-infected people are inadequate [2].
Therefore, identifying novel TB diagnostics is a major
international public health priority [3]. Interferon gamma
(IFN-γ) release assays (IGRA) are under active investiga-
tion for the diagnosis of latent and active TB [4-7]. Since
diminished IFN-γ release is a cardinal antimycobacterial
immune defect in HIV-infected people [8-14], and vulner-
ability to active TB in HIV-infected people increases with
increasing immunodeficiency [15], HIV-related immuno-
deficiency has the potential to compromise IGRA accu-
racy. Thus, it will be important to investigate additional
methods of diagnosing latent and active TB.
Antimycobacterial lymphocyte proliferation is also detect-
able in HIV-infected subjects with latent and active TB
[8,16-18], and therefore merits investigation for the diag-
nosis of latent and active TB in HIV infection. However,
because antimycobacterial lymphocyte proliferation can
also be impaired during HIV infection [8,16,17], it will be
important to evaluate the relation between stage of HIV
disease and LPA diagnostic utility. Accordingly, we evalu-
ated LPA responses in subjects with and without latent or
active TB in a cohort of HIV-infected BCG-immunized
subjects with CD4 counts ≥ 200 cells/mm3 entering a TB
booster vaccine trial in Tanzania [19,20]. This is the first
report to characterize the diagnostic characteristics of LPA
during active TB.
Methods
Study subjects and data collection
The Dar Dar Study was a phase III randomized placebo-
controlled trial of a prime-boost vaccine strategy for the
prevention of HIV-associated tuberculosis in adults in Dar
es Salaam, Tanzania [20]. Enrollment for this study
occurred from 2001 to 2005, and study follow up contin-
ued through January 2008. All subjects were screened with
a standardized interview, including history of prior treat-
ment for active tuberculosis, physical examination, CD4
count and single view chest x-ray. Eligible subjects who
gave informed consent were enrolled if they have two pos-
itive ELISA antibody tests for HIV, a CD4 count ≥ 200/
mm3, a BCG scar and no evidence of active tuberculosis
(TB). At enrollment, subjects were further evaluated with
three expectorated sputum samples collected for AFB
smear and culture, and a single mycobacterial blood cul-
ture. Per protocol, subjects with active TB detected imme-
diately at baseline were ineligible for enrollment and thus
discharged from the study with immunological studies
not performed. In contrast, subjects with baseline active
TB that was not detected immediately, but later identified
via baseline mycobacterial cultures of sputum or blood,
were not yet discharged from the study and as a result had
immunological tests performed. Subjects in this latter cat-
egory, with delayed recognition of baseline TB on whom
immunological studies were performed, are the subject of
this report. Human experimentation guidelines of the
United States Department of Health and Human Services,
as well as that of the Committee for the Protection of
Human Subjects at Dartmouth College and the Research
Ethics Committee of the Muhimbili University of Health
and Allied Sciences, were followed in the conduct of this
research. This study is registered through the National
Institutes of Health (NCT00052195).
Definitions of TB
Subjects with a reactive tuberculin skin test (TST) at ≥ 5
mm but no active TB were deemed to have latent TB. Sub-
jects were designated as having active TB if they met a
study definition of definite or probable TB as determined
by the consensus of a three person expert panel (Table 1).
Tuberculin skin testing
All subjects underwent TST with 0.1 mL tuberculin (RT-
23, State Serum Institute, Copenhagen) as well as with 0.1
mL Mycobacterium avium sensitin (MAS, State Serum Insti-
tute, Copenhagen). The size of skin induration at the site
at 48–72 hours was measured, and reactions ≥ 5 mm were
considered positive.
Lymphocyte proliferation assays (LPA)
LPA were conducted on freshly isolated and ficolled
peripheral blood mononuclear cells using a standard five
day  3H-thymidine incorporation method with media
alone, 1 mcg/ml M. tuberculosis ESAT-6, 0.5 mcg/ml M.
tuberculosis Ag85, or 0.5 mcg/ml M. tuberculosis whole cell
lysate (WCL), with all antigens acquired through NIH,
NIAID Contract No. HHSN266200400091C, entitled
"Tuberculosis Vaccine Testing and Research Materials,"
awarded to Colorado State University. After incubation,
20 μl of 50 μCi/ml 3H-thymidine was added to wells for
24 hours, after which the cells were harvested onto filter
paper and sent to the National Public Health Institute in
Helsinki, Finland, for data acquisition on a scintillation
counter. Results were expressed as a proliferation index
(PI; counts per minute [CPM] of antigen stimulated cells
divided by CPM of unstimulated cells), with a prolifera-
tion index of ≥ 5 considered positive. LPA results are
shown for all assays, but equivalent results were derived
when identical analyses were undertaken after excluding
assays if the positive control (phytohemagglutinin [PHA]
2.5 μg/ml) PI was < 3, or less than the unstimulated con-
dition, or if the CPM for the unstimulated cells was over
5000.
Supernatant IFN-  levels
IFN-γ levels in frozen cell culture supernatants were eval-
uated after 5-day stimulation with the same antigensBMC Infectious Diseases 2009, 9:21 http://www.biomedcentral.com/1471-2334/9/21
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using a standard enzyme linked immunosorbent assay
(ELISA; R&D Systems). Results were considered positive if
IFN-γ level was greater than or equal to two standard devi-
ations above the negative mean.
Statistical analysis
Standard descriptive statistical methods were used to char-
acterize baseline demographical characteristics of the
study population. Comparisons between demographic
characteristics and immune responses between subjects
with no TB, latent TB and active TB were made using anal-
ysis of variance (ANOVA). Comparisons between two
groups were made using t tests. P values less than 0.05
were considered statistically significant. The diagnostic
utility of immune responses in TB was assessed using
receiver-operating characteristic (ROC) analysis. Agree-
ment between tests was assessed using Spearman's rank
correlation coefficients. Trends in the relation between the
Table 1: Case definitions.
Definite TB 1. One or more sputum cultures positive for Mycobacterium tuberculosis (MTB) with ≥ 10 colony forming units (CFU); or,
2. Two or more sputum cultures with 1–9 CFU of MTB (indeterminate MTB culture); or,
3. Two or more positive sputum smears for acid fast bacilli (AFB); or,
4. One or more cultures for MTB from the blood or other sterile body site.
Probable TB 1. Positive chest x-ray plus either
a. one positive sputum AFB smear, or,
b. one indeterminate MTB culture result; or,
2. Clinical symptoms/signs plus either
a. one positive sputum AFB smear, or,
b. one indeterminate MTB culture result; or,
3. Clinical symptoms/signs and a positive x-ray plus a response to anti-TB therapy; or,
4. One positive sputum AFB smear from a sterile site plus clinical symptoms/signs of tuberculosis; or,
5. Caseous necrosis on a tissue biopsy.
Latent TB 1. Tuberculin skin test ≥ 5 mm
2. No definite or probable TB.
AFB, acid fast bacillus; CFU, colony forming units; MTB, Mycobacterium tuberculosis; TB, tuberculosis
Table 2: Characteristics of study subjects.
Subjects without TB
(n = 1206)
Subjects with latent TB
(n = 635)
Subjects with active TB
(n = 13)
P-value by ANOVA
Age, mean 33.0 33.5 34.1 0.5102
Male, % (n) 247 (20.5%) 193 (30.4%) 3 (23.1%) < 0.0001
CD4 cells/mm3, mean 455 502 376 0.0001
HIV viral load, copies/mL, mean 37,286 28,365 87,293 0.0063
Previous TB, % (n) 98 (8.1%) 61 (9.6%) 2 (15.4%) 0.3865
On antiretrovirals, % (n) 44 (3.6%) 13 (2.0%) 0 (0%) 0.1366
TST, mm, mean 0.2 15.5 15.0 < 0.0001
TST ≥ 5 mm, % (n) 0 (0%) 635 (100%) 11 (84.6%) < 0.0001
MAS, mm, mean 0.3 9.6 10.1 < 0.0001
MAS ≥ 5 mm, % (n) 835 (69.2%) 582 (91.7%) 10 (76.9%) < 0.0001
ANOVA = analysis of variance; HIV = human immunodeficiency virus; MAS = Mycobacterium avium sensitin skin test; TB = tuberculosis; TST = 
tuberculin skin testBMC Infectious Diseases 2009, 9:21 http://www.biomedcentral.com/1471-2334/9/21
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risk of TB and the number of antimycobacterial immune
responses were evaluated using the score test for trend of
odds. Parameters demonstrating differences between TB
and no TB groups in univariate analyses were incorpo-
rated into a logistic regression model. Correlations
between the results of in vivo and in vitro immune assays,
and with clinical parameters, utilized the Pearson chi-
squared test. Data were analyzed on STATA 9 (College Sta-
tion, TX) and Graph Pad Prism 4 (San Diego, CA).
Results
The characteristics of the study subjects are shown in
Table 2, including the 13 with delayed recognition of
active TB at baseline. All subjects were HIV positive, had
BCG scars and CD4 counts ≥ 200/mm3. Evaluable LPA
results were available in 1855 subjects: IFN-γ results in
1542 subjects and TST results in 1815 subjects. Thirteen
subjects had positive sputum cultures for MTB; eleven fit
study criteria for definite TB and two for probable TB. Sub-
jects with active TB had higher mean HIV viral loads
(87,292.6 vs. 34023.0 copies/mL, P = 0.0066), and were
more likely to have a positive TST (84.6% vs. 34.5%, P =
0.0002) when compared to all subjects without active TB.
LPA results during latent and active TB
Figure 1A and Table 3 show the LPA responses to myco-
bacterial antigens in subjects with no TB, latent TB and
with active TB. Compared to subjects without TB, detecta-
ble LPA responses to ESAT-6, Ag85 and WCL were signifi-
cantly more common in subjects with latent and active
TB. A pattern of increasing LPA responses to all three anti-
gens was seen when moving from no TB to latent TB to
active TB.
Agreement of LPA results
There was a significant correlation between LPA responses
to different mycobacterial antigens: ESAT-6 vs. Ag85,
Spearman's rho 0.4242, P < 0.0001; ESAT-6 vs. WCL,
Spearman's rho 0.3646, P < 0.0001; Ag85 vs. WCL, Spear-
man's rho 0.4033, P < 0.0001.
LPA responses by TST status during active TB
We compared LPA responses in subjects with active TB to
LPA responses in all other subjects. In subjects with a pos-
itive TST, TB was more likely in subjects with detectable
LPA responses to ESAT-6 (P < 0.0001), Ag85 (P < 0.0001)
and WCL (P < 0.0001). The specificity of LPA to ESAT-6
and Ag85 was over 80% in subjects with a positive TST
(Table 4).
LPA results according to TST status in subjects without 
active TB
In the group of patients without active TB at baseline,
detectable LPA responses were more common in subjects
with a positive TST: ESAT-6 13.2% vs. 5.5%, P < 0.0001;
Ag85 18.7% vs. 3.1%, P < 0.0001; and, WCL 45.7% vs.
17.1%, P < 0.0001.
LPA operating characteristics
The sensitivity and specificity of TST for detecting TB were
84.6% and 65.5%, respectively. As shown in Table 4 the
sensitivity of LPA assays was lower than TST in every case,
but antimycobacterial LPA assays were generally more
specific. The area under the ROC curve (AUROC) for TST
was higher than for LPA at either PI cutoff. The positive
predictive values for LPA responses to all antigens were
low, as for TST. The negative predictive values for all LPA
assays were approximately 99% regardless of TST status.
Assay operating characteristics were not improved when
combining multiple antigen responses (data not shown).
LPA responses and CD4 count or HIV viral load
There was a weak but statistically significant negative cor-
relation between CD4 count and the likelihood of LPA
responses to ESAT-6 (Pearson r -0.1044, P < 0.0001),
Ag85 (Pearson r -0.0744, P = 0.0013) and WCL (Pearson
r -0.1162, P < 0.0001). In subjects stratified by CD4 count,
LPA responses showed the same increasing pattern from
no TB to latent TB to active TB, but in the low CD4 count
group LPA was generally less able to discriminate between
latent and active TB (Figures 1B-1C). No LPA response
could discriminate subjects with latent TB from active TB
in the CD4 < 350 stratum. The HIV viral load correlated
weakly but positively with the likelihood of detectable
LPA responses to ESAT-6 (Pearson r 0.1577, P < 0.0001),
Ag85 (Pearson r 0.1277, P = 0.0008), and WCL (Pearson
r 0.1131, P = 0.0029). Because of the relation of LPA
responses to CD4 count and HIV viral load, we stratified
our analysis of the correlation between active TB and the
antimycobacterial immune response by CD4 count and,
separately, HIV viral load (Table 5), finding that detecta-
ble mycobacterial LPA responses were associated with
higher odds of TB at higher CD4 counts and higher HIV
viral loads.
Multiple LPA responses related to greater TB risk
Figure 2 shows the relation between the number of
antimycobacterial responses by LPA and the odds of TB.
An increasing number of antimycobacterial LPA responses
were associated with increasing odds of TB (P = 0.0097).
Multivariate model
In a multivariate logistic regression analysis adjusting for
factors that differed between subjects with and without
active TB, active TB was associated with LPA responses to
ESAT-6 (OR 3.8, P = 0.036) and Ag85 (OR 3.2, P =
0.0760).
IFN-  results during latent and active TB
IFN-γ responses were more common in subjects with
latent TB compared to those without TB (ESAT-6, 49.3%BMC Infectious Diseases 2009, 9:21 http://www.biomedcentral.com/1471-2334/9/21
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Lymphocyte proliferation to mycobacterial antigens in subjects with a spectrum of tuberculosis Figure 1
Lymphocyte proliferation to mycobacterial antigens in subjects with a spectrum of tuberculosis. The percentage 
of subjects with lymphocyte proliferation index of ≥ 5 to the indicated antigens is compared in subjects with active TB, latent 
TB and no TB in (A) all subjects, (B) subjects with a CD4 count < 350 cells/ul, and (C) subjects with a CD4 count ≥ 350 cells/
ul. The proliferation index is the ratio of counts per minute after stimulation with indicated antigen over counts per minute in 
unstimulated condition. (Ag85, antigen 85; ESAT-6, early secretory antigenic target 6; LTBI, latent tuberculosis infection; TB, 
tuberculosis; WCL, Mycobacterium tuberculosis whole cell lysate)BMC Infectious Diseases 2009, 9:21 http://www.biomedcentral.com/1471-2334/9/21
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vs. 26.6%, P < 0.0001; Ag85, 38.6% vs. 24.8%, P < 0.0001;
WCL, 78.4% vs. 42.8%, P < 0.0001), but IFN-γ responses
were not consistently different between subjects with and
without active TB (ESAT-6, 38.5% vs. 26.6%, P = 0.3366;
Ag85, 23.1% vs. 24.8%, P = 0.8881; WCL, 76.9% vs.
42.8%, P = 0.0133). There was, however, a clear differen-
tiation between IFN-γ responses to the positive control
condition (PHA) compared to medium in all subjects
(83.2% vs. 18.6%, P < 0.0001), in subjects without TB
(85.0% vs. 19.6%, P < 0.0001), in subjects with latent TB
(79.7% vs. 16.9%, P < 0.0001), and in subjects with active
TB (69.2% vs. 15.4%, P = 0.0028). The absolute CD4
count correlated with the likelihood of having demonstra-
ble IFN-γ responses to each mycobacterial antigen: ESAT-
6, Pearson r = 0.1076, P < 0.0001; Ag85 Pearson r =
0.0488, P < 0.0356; and WCL Pearson r = -0.0868, P =
0.0002. By contrast, the HIV viral load weakly impacted
only the likelihood of positive responses to ESAT-6, Pear-
son r = 0.0801, P = 0.0354.
Discussion
An international effort is underway to find novel means of
diagnosing and predicting TB in people with HIV [3]. We
have shown that LPA responses to multiple mycobacterial
antigens are enhanced during latent and active TB in HIV-
infected subjects with CD4 counts ≥ 200 cells/mm3 and
prior BCG immunization, and that these responses are
less sensitive but more specific than TST in diagnosing
active TB.
No previous studies have examined the diagnostic utility
of LPA responses during active TB in HIV-infected adults.
One group showed that LPA responses to mycobacteria
were detectable in HIV-infected adults with TB, and noted
a decline in response frequency at lower CD4 counts and
in comparison to subjects without HIV [8]. However, only
67% of patients in that study were BCG immunized, LPA
responses were not characterized according to BCG
immunization or TST status, and the diagnostic operating
characteristics of the test were not explored. In a prelimi-
Table 3: Prevalence of detectable lymphocyte proliferation to mycobacterial antigens in HIV-infected BCG-vaccinated adults with and 
without active TB.
Antigen Subjects without TB
(n = 13)
Subjects with latent TB
(n = 635)
Subjects with active TB
n = 1206)
P-value by ANOVA
PHA, % (n) 543 (45.0%) 278 (43.8%) 8 (61.5%) 0.4175
MVS, % (n) 26 (2.2%) 21 (3.3%) 0 (0%) 0.2756
ESAT-6, % (n) 66 (5.5%) 84 (13.2%) 5 (38.5%) < 0.0001
Ag85, % (n) 38 (3.1%) 119 (18.7%) 6 (46.2%) < 0.0001
WCL, % (n) 207 (17.1%) 290 (45.7%) 8 (61.5%) < 0.0001
Ag85, antigen 85; ESAT-6, early secretory antigenic target 6; MVS, Mycobacterium vaccae sonicate; PHA, phytohemagglutinin; TB, tuberculosis; WCL, 
Mycobacterium tuberculosis whole cell lysate
Table 4: Operating characteristics of TST and LPA assays for the diagnosis of active TB.
All subjects Subjects with TST   5 mm
Sensitivity, % Specificity, % AUROC PPV NPV Sensitivity, % Specificity, % AUROC PPV NPV
TST 84.6 65.5 0.7507 1.7 99.8 -- -- -- -- --
ESAT-6 38.5 92.0 0.6516 3.2 99.5 45.5 86.8 0.6611 5.6 98.9
Ag85 46.2 91.5 0.6882 3.68 99.6 54.6 81.3 0.6790 4.8 99
WCL 61.5 73.0 0.6728 1.58 99.6 72.7 54.3 0.6353 2.68 99.1
Ag85, antigen 85; AUROC, area under the receiver-operating characteristic curve, calculated as sensitivity plotted against 1-specificity; ESAT-6, 
early secretory antigenic target 6; LPA, lymphocyte proliferation assay; NPV, negative predictive value; PPV, positive predictive value; TB, 
tuberculosis; TST, tuberculin skin test; WCL, Mycobacterium tuberculosis whole cell lysateBMC Infectious Diseases 2009, 9:21 http://www.biomedcentral.com/1471-2334/9/21
Page 7 of 10
(page number not for citation purposes)
nary report on seven of the subjects with HIV and active
TB described in the present study we showed that LPA
responses to mycobacterial antigens were detectable but
did not determine the operating characteristics of the LPA
nor the relation of these results to CD4 counts or HIV viral
load [18]. Others have detailed LPA responses to PPD and
mycobacterial cell cultures in HIV-infected adults with
latent TB [16,17], but these studies lack a description of
the impact of HIV-related immunodeficiency or HIV viral
load on assay results. Taken together, our data newly show
that LPA responses to mycobacterial antigens are capable
of detecting a spectrum of TB disease from latent to active
and disseminated disease.
The ongoing search for novel TB diagnostic approaches in
HIV-infected individuals results from the limitations of
the TST in HIV-infected individuals, including decreased
sensitivity at low CD4 counts and the potential for false
positive results after BCG vaccination [21-23]. Here, we
have shown that LPA is less sensitive than TST, but more
specific. Importantly, we did not examine the comparative
sensitivity of LPA and TST at CD4 counts under 200 cells/
ul, since all subjects in this study had CD4 counts over
200 cells/ul. Since other immunological assays for the
detection of TB have shown increased sensitivity when
responses against multiple antigens were combined
[4,24], this approach has the potential to increase LPA
sensitivity. The higher specificity of LPA likely results from
the use of more TB-specific antigens ESAT-6 and Ag85,
and is particularly important in BCG-immunized subjects
such as are prevalent in areas of high TB endemicity. Even
in subjects with a positive TST, subjects lacking LPA
responses to mycobacterial antigens were highly unlikely
to have active TB.
IGRA's are the current frontrunners in the race to replace
TST [4,5,25]. The sensitivity of detectable LPA responses
to mycobacterial antigens reported here is lower than that
reported previously for IGRA assays during active TB. This
may be due to different test characteristics of IGRA vs LPA,
or the fact that commercial IGRA assays employ a myco-
bacterial antigen (CFP-10) that we did not use in the
present LPA assay. IGRA sensitivity in HIV-infected sub-
jects who recently completed therapy for TB was 71–81%,
Table 5: Odds of active TB according to lymphocyte proliferation assays, stratified by CD4 count and HIV viral load.
Odds of TB if PI ≥ 5 to Antigen
By CD4 count strata By HIV Viral Load Quartile
Antigen CD4 count ≥ 350* CD4 count < 350 P value by Mantel-Haenszel 
method
Lowest Second Third Highest P value by Mantel-Haenszel 
method
ESAT-6 15.8 2.9 0.0003 0 0 12.2 6.8 0.0030
Ag85 15.2 5.9 < 0.0001 0 0 11.2 7.1 0.0022
WCL 3.3 4.8 0.0098 0 0 0 2.7 0.0333
* Of subjects with active TB, six had CD4 counts ≥ 350
Ag85, antigen 85; ESAT-6, early secretory antigenic target 6; PI, proliferative index; TB, tuberculosis; WCL, Mycobacterium tuberculosis whole cell 
lysate
Odds of active TB according to number of detectable antimy- cobacterial lymphoproliferative responses Figure 2
Odds of active TB according to number of detectable 
antimycobacterial lymphoproliferative responses. 
(LPA, lymphocyte proliferation assays; TB, tuberculosis)
01234
0.00
0.02
0.04
Number of LPA responses
O
d
d
s
 
o
f
 
T
BBMC Infectious Diseases 2009, 9:21 http://www.biomedcentral.com/1471-2334/9/21
Page 8 of 10
(page number not for citation purposes)
whereas during culture positive TB in HIV-infected sub-
jects the sensitivity of IGRA was 85% [26,27]. In both
studies, BCG vaccination was not universal, although in
both papers the authors reported that BCG immunization
had no impact on IGRA sensitivity.
Improving the sensitivity of LPA during active HIV-associ-
ated TB nonetheless will be critical, as the sensitivity val-
ues we observed are inadequate for clinical use. However,
LPA sensitivity may be increased by using alternate TB
antigens in combination, such as was done with IGRA
[24]. Furthermore, we suspect the estimates of LPA sensi-
tivity in our study are conservative, since the subjects with
active TB reported here were diagnosed late after being
scrutinized for clinical trial enrollment, and thus may
have more clinically and immunologically subtle TB dis-
ease than would be identified during routine clinical care.
The specificity of LPA assays in the present study is similar
to that of IGRA. IGRA specificity has been reported to be
98.6% during active TB in HIV-negative subjects in Japan,
[5], but in areas with high TB prevalence rates this figure
is expected to be lower [28]. Accordingly, in BCG-immu-
nized and HIV positive adults without active TB in Zam-
bia, the specificity of IGRA was 71% for responses to
ESAT-6 alone and 57% to ESAT-6 and CPT-10 combined
[24]. These specificity values are lower than those we
report for LPA, although no head-to-head comparison has
yet been done. Since the TB epidemic flourishes largely in
high prevalence areas where BCG vaccination is common,
and in people with HIV co-infection, we believe it will be
important to evaluate alternate platforms for diagnosing
TB or TB risk in HIV-infected subjects from high TB prev-
alence areas [25].
Our data show that LPA responses are more predictive of
TB risk in subjects with higher CD4 counts [16,17].
Importantly, all subjects in this study had CD4 counts
above 200 cells/mm3, so it will be important to evaluate
the diagnostic utility of LPA in subjects with more pro-
found HIV-related immunodeficiency. This is particularly
important since IGRA based on the enzyme-linked immu-
nospot (ELISPOT) technique appear not to lose sensitivity
at lower CD4 counts [29,30] although the impact of pro-
gressive HIV-related immunodeficiency on IGRA accuracy
is still under study. While in prior studies antiretroviral
therapy increased the likelihood of detectable LPA
responses, patients in our cohort with higher HIV viral
loads were more likely to have detectable lymphoprolifer-
ative responses to mycobacteria. Since antiretroviral ther-
apy was rare in our cohort, the viral loads reported here
reflect untreated values, and thus we posit that the rela-
tion between the HIV viral load and TB risk is different in
untreated vs. treated subjects. It is possible that a high HIV
viral load off therapy may contribute to greater HIV-
related immunological dysfunction and thus vulnerability
to TB disease, whereas treated patients with a lower viral
load on therapy may be more likely to have detectable
responses via antimycobacterial immune reconstitution.
It is also possible that the higher viral loads were a conse-
quence of new active TB [31].
HIV and TB intersect most lethally in the developing
world. Thus, it is important to consider whether conduct-
ing the LPA – a complicated five day assay involving low-
level radioactivity – is feasible in the developing world.
We generated these data in Tanzania, but the assessment
of lymphocyte radioactivity (which is proportionate to
proliferation in this assay) was carried out in Finland. Fur-
ther, all assays were conducted through a US-funded clin-
ical trial with an intensive focus on quality control.
Accordingly, we suspect that only larger medical centers in
the developing world would have the capacity to conduct
LPA assays.
Despite an extensive literature that suggests that IFN-γ
responses to mycobacterial antigens are decreased but
detectable in HIV-infected individuals [8,10,14,26,27],
we did not see differences in IFN-γ responses in subjects
with and without TB. One reason for this discrepancy may
be differential assay duration. While the IFN-γ results here
stem from five day incubation assays, currently commer-
cially available assays employ one day of incubation. One
day assays measure effector cell IFN-γ release, while five
day assays likely measure IFN-γ release from effector and
central memory T cells [32,33]. As a result, our five day
IFN-γ assays may fail to discriminate between subjects
with novel effector T cell responses generated during
active TB and those with pre-existing memory T cell
responses to TB. Despite careful attention to quality con-
trol in this developing world setting, a small proportion of
IFN-γ assays lacked PHA responses or had detectable
responses to the medium control. Assay failure thus has
the potential to contribute to our IFN-γ assay's inability to
detect differences between subjects with active TB or no
TB, although notably the assay did discriminate between
subjects with latent TB and no TB. Another potential rea-
son for the discrepant IFN-γ results in this study is that cer-
tain mycobacterial antigens may be more efficient at
generating IFN-γ responses than others. Commercially
available assays of IFN-γ target ESAT-6 as well as CFP-10
with and without TB7.7 [4,25], and others have demon-
strated detectable IFN-γ responses in HIV-infected subjects
with active TB using purified protein derivative (PPD)
[8,14] Our assay, which assessed responses to ESAT-6,
Ag85 and WCL, may be less likely to generate IFN-γ
responses that distinguish between subjects with and
without TB. At a minimum, our data suggest that incuba-
tion period and antigen choice are critical variables in
IFN-γ assays for TB.BMC Infectious Diseases 2009, 9:21 http://www.biomedcentral.com/1471-2334/9/21
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Our data show that detectable LPA responses to TB are
associated with TB infection, but not necessarily with
effective cellular immune protection against disease. This
is consistent with the known association between TST
results and TB risk [34,35]. This model has important
implications regarding the conduct of TB vaccine trials: it
will be vitally important to determine not only whether
TB vaccines generate antimycobacterial immune
responses, but whether these immune responses correlate
with disease protection.
Conclusion
In conclusion, an assay of antimycobacterial lymphocyte
proliferation was more specific but less sensitive than TST
in detecting active TB in HIV-infected and BCG-immu-
nized patients from a high TB prevalence area. Given the
potential for improving LPA sensitivity by using a differ-
ent panel of mycobacterial antigens and assessing it in
subjects with more clinically overt active TB, LPA merits
continued evaluation as a novel diagnostic tool for HIV-
associated TB.
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